# LIPELLA PHARMACEUTICALS INC (LIPOXXXX)

> Institutional ownership reported to the SEC as of Q3 2024, from Form 13F filings. Source: https://holderbook.com/stocks/LIPOXXXX/

- Reporting holders: 5
- Reported value: $39.7K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [VANGUARD GROUP INC](https://holderbook.com/funds/102909-vanguard-group-inc/) | $16.3K | 34,520 | 0.0% | 7 |
| [GEODE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1214717-geode-capital-management-llc/) | $11.8K | 24,915 | 0.0% | 4 |
| [HRT FINANCIAL LP](https://holderbook.com/funds/1475597-hrt-financial-lp/) | $8.0K | 17,619 | 0.0% | 1 |
| [Tower Research Capital LLC (TRC)](https://holderbook.com/funds/1533421-tower-research-capital-llc-trc/) | $3.6K | 7,694 | 0.0% | 7 |
| [BANK OF AMERICA CORP /DE/](https://holderbook.com/funds/70858-bank-of-america-corp-de/) | $22 | 47 | 0.0% | 2 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2024 | 5 | $39.7K |
| Q2 2024 | 7 | $284.0K |
| Q1 2024 | 9 | $260.1K |
| Q4 2023 | 7 | $377.4K |
| Q3 2023 | 4 | $59.5K |
| Q2 2023 | 4 | $82.5K |
| Q1 2023 | 6 | $103.7K |
| Q4 2022 | 2 | $44.7K |